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Abstract Hypoxia-inducible factor-1 (HIF-1) is a transcription
factor activated by hypoxia. The HIF-1 activation transduction
pathway is poorly understood. In this report, we investigated the
activation of extracellular regulated kinases (ERK) in hypoxia
and their involvement in HIF-1 activation. We demonstrated that
in human microvascular endothelial cells-1 (HMEC-1), ERK
kinases are activated during hypoxia. Using dominant negative
mutants, we showed that ERK1 is needed for hypoxia-induced
HIF-1 transactivation activity. Moreover, using a kinase assay
and Western blot experiments, we showed that HIF-1K is
phosphorylated in hypoxia by an ERK-dependent pathway.
These results evidence the role of mitogen-activated protein
kinase in the transcriptional response to hypoxia.
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1. Introduction
Vascular injuries, ischemic cardiovascular diseases and
thrombosis provoke pathological decreases in oxygen tension
[1,2]. In response to these hypoxic conditions, mammalian
cells increase the expression of genes encoding proteins in-
volved in the anaerobic production of ATP (aldolase A, eno-
lase-K, GLUT-1, etc. [1]). Hypoxic cells also secrete VEGF, an
angiogenic hormone [1]. HIF-1 transcription factor is acti-
vated by hypoxia and is responsible for these modi¢cations
in gene expression.
HIF-1 is a heterodimeric protein composed of the HIF-1K
and ARNT sub-units [3]. These two sub-units belong to the
basic helix-loop-helix (bHLH)-PAS protein family [3,4]. HIF-
1K is the sub-unit regulated by hypoxia.
In normoxia, HIF-1K is a cytosolic protein rapidly de-
graded by the ubiquitin-proteasome pathway [5]. This degra-
dation is mediated by the oxygen-dependent degradation
domain (ODD, residues 401^603) [6]. In hypoxia, the deg-
radation of HIF-1K is inhibited. The protein is then trans-
located into the nucleus where it dimerizes with ARNT [7],
a nuclear protein [8]. HIF-1 then binds to the hypoxia respon-
sive element (HRE) [9] cis-elements found in promoters or
enhancers.
The mechanisms of activation of HIF-1 are currently
poorly understood. Phosphorylations seem to be involved
for the stabilization of the HIF-1K sub-unit in hypoxia. In-
deed, kinase inhibitors are able to impair the HIF-1K stabili-
zation in hypoxia [10]. Moreover, Semenza et al. demon-
strated that the carboxy terminal domain of HIF-1K is
composed of three distinct domains [11] : transactivation do-
main-N terminal (TAD-N, residues 531^575) and TAD-C
(transactivation domain-C terminal, residues 786^826) and
the ID (inhibitory domain, residues 576^785) [11]. The
TAD-C and the TAD-N are involved in hypoxia in the tran-
scriptional activity induced by a GAL-4/HIF-1K chimeric pro-
tein [11]. The expression level of these fusion proteins was the
same in normoxia and in hypoxia [11]. The ID is able to
inhibit the normoxic transcriptional activity of the TAD-N/
C without a¡ecting the fusion protein stability [11]. These
results indicate that the increase in gene expression induced
by HIF-1 in hypoxia ¢rstly requires the stabilization of the
HIF-1K sub-unit and secondly the activation/derepression of
the carboxy-terminal domain of HIF-1K. The activation of the
TAD-N/C could occur by interaction with co-activator (CBP/
p300) [12], and/or by phosphorylation(s) [11,13]. The inhibi-
tion of the ID domain in hypoxia could also occur by phos-
phorylations [11].
In this report, we investigated the role of the mitogen-acti-
vated protein kinases (MAPK) ERK1 and ERK2 in the acti-
vation of HIF-1 by hypoxia in endothelial cells. Firstly, we
showed that ERK1 and ERK2 are activated during hypoxia.
Inhibition of these kinases with PD98059 [14] did not inhibit
the hypoxic stabilization of the HIF-1K sub-unit nor did it
inhibit the DNA binding activity of HIF-1. However, in cells
treated with PD98059, we observed the inhibition of the HIF-
1 transcriptional activity induced by hypoxia. Moreover, the
HIF-1-induced transcriptional activity was inhibited in hy-
poxic human microvascular endothelial cells-1 (HMEC-1) ex-
pressing ERK1 but not ERK2 dominant negative mutant. At
last, hypoxically activated ERK1 is able to directly phosphor-
ylate the carboxy-terminal domain of HIF-1K. These results
show that ERK1 is involved in the hypoxia-induced transcrip-
tional activity of HIF-1 but that this kinase does not partic-
ipate in the stabilization of the HIF-1K protein.
2. Materials and methods
2.1. Cell culture
HMEC-1 [15] were grown in MCDB 131 (Gibco, UK) containing
15% fetal calf serum, 10 ng/ml epidermal growth factor (EGF), 1 Wg/
ml hydrocortisone, 10 mM glutamine, 50 U/ml penicillin G, 50 ng/ml
amphotericin B. 24 h prior hypoxia, the cells were incubated in
MCDB 131 containing 0.2% serum and without EGF. Normoxia
(21% O2) and hypoxia (1% O2) incubations were performed in CO2-
independent medium (Gibco, UK) supplemented with 10 mM gluta-
mine, 1 Wg/ml hydrocortisone, 50 U/ml penicillin G, 50 ng/ml ampho-
tericin B and 0.2% serum. COS-7 cells were grown in DMEM con-
taining 20 mM HEPES pH 7.2, 50 U/ml penicillin G, 50 ng/ml
amphotericin B and 10% fetal calf serum.
2.2. Western blot analysis
Total cell extracts were prepared from HMEC-1 grown in 25 cm2
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£asks. The cells were incubated in normoxia or in hypoxia. Then the
cells were washed with ice-cold PBS and lysed using the extraction
bu¡er (Tris 40 mM pH 7.5, KCl 300 mM, EDTA 2 mM, Triton X-
100 1%, protease and phosphatase inhibitors). The lysate was incu-
bated on ice for 30 min, centrifuged 15 min at 15 000 rpm, 4‡C, and
the clear lysate was boiled and kept frozen until use. The di¡erent
extracts were resolved on SDS^PAGE gels and then transferred to
PVDF membrane. After blocking in phosphate saline bu¡er contain-
ing 0.2% Tween and 5% dried milk, the blot was probed with the
suitable antibody. The phospho-speci¢c p44/p42 MAPK antibody
(Westburg, Biolabs, UK) [16] was used (1/5000) to detect phospho-
ERKs, monoclonal anti-ERK2 and monoclonal anti-ERK1 antibod-
ies (PharMingen, Becton Dickinson, USA) were used (1/2000) to
probe total ERK1 and ERK2. Anti-HIF-1K (Transduction Laborato-
ries, Becton Dickinson, UK) was used to probe HIF-1K (1/1000) and
anti-K-tubulin (1/2000) (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) was used to probe tubulin as control of loaded protein amount.
Horseradish peroxidase-conjugated secondary antibodies (Amersham
Pharmacia, Sweden) were used (1/2000) for detection by chemilumi-
nescence.
2.3. Immuno£uorescence
HMEC-1 were grown on glass coverslip. The cells were incubated
during 2 h in normoxia or in hypoxia. Then the cells were washed
with PBS and ¢xed 10 min with PBS containing 4% paraformalde-
hyde. The ¢xed cells were washed three times with PBS+BSA 3%, the
cells were incubated 2 h with either an anti-ERK1 or an anti-ERK2
antibody (1/2000) (Transduction Laboratories, Becton Dickinson,
USA) in PBS+BSA 3%. Then the cells were washed three times
with PBS+BSA and secondary anti-mouse TRITC-conjugated anti-
bodies were added to the cells (1/2000). After 1 h of incubation, the
cells were washed three times with PBS+BSA before ¢xation in mo-
wiol. Observation were performed using a confocal microscope (Leica,
Germany).
2.4. Immunoprecipitations and kinase assay
Total cell extracts from normoxic and hypoxic cells incubated in the
presence or in the absence of PD98059 20 WM (Calbiochem) were
prepared as described above. After having collected the supernatant,
ERK1 (Santa Cruz Biotechnology) or ERK2 (PharMingen Interna-
tional, Becton Dickinson, USA) antibodies (1/1000) were added to the
samples followed by an incubation of 2 h at 4‡C. The immune com-
plexes were immobilized with 40 Wl of Sepharose-protA beads and
incubated for 2 h, followed by three washes with 800 Wl of cold lysis
bu¡er. An additional washing step was performed with 800 Wl of
kinase assay bu¡er (25 mM HEPES pH 7.6, 20 mM MgCl2, Na3VO4
0.1 mM, DTT 2 mM). 100 Wl of each sample were kept for Western
blot analysis. The beads with ERK kinase were collected by centrifu-
gation and resuspended in 40 Wl of kinase assay bu¡er. 2 Wl of ATP
1 mM, 1 Wl of [Q-32P]dATP (10 WCi) and 2 Wg of ERKs-peptide sub-
strate (Santa Cruz Biotechnology) (RRRELVEPLTPSGE) were
added to the assay mix. The mix was incubated 30 min at 37‡C and
the reaction was stopped by boiling. Then the peptide was adsorbed
on phosphocellulose SpinZyme membranes (Pierce, USA). The mem-
branes were placed into a scintillation vial and the radiolabelled pep-
tide of each sample was quantitated using a scintillation counter.
2.5. Transient transfection and reporter gene assays
To assay the transcriptional activity of HIF-1, we used the pGL3-
SV40HRE vector which contains three copies of the EPO HRE down-
stream from the luciferase gene of which the expression is driven by a
heterologous SV40 promoter [17]. The pGL3-SV40 was used as neg-
ative control and does not respond to hypoxia (not shown in ¢gures)
[9,17]. HMEC-1 transfection was performed in a 96-well plate at 80%
con£uency. These vectors were co-transfected with the control vector
pRL-SV40 (Promega, USA) as transfection e⁄ciency control. Regard-
ing the dominant negative vectors, we used ERK1 (pcDNA-ERK1-)
and ERK2 (pcDNA-ERK2-) dominant negative expression vectors
which encode ERKs mutated in their ATP binding sites [18] and as
null vector, we used the pBSKII+ (Stratagene, USA). 3 Wg of DOTAP
transfection reagent (Boehringer, Germany) were mixed with a total
of 500 ng of the described plasmids. The transfection solution was
added to the cells for 4 h. The cell medium was replaced with CO2-
independent medium. Thereafter, the transfected cells were placed in
either normoxia or hypoxia for 24 h. After the incubation, the lucif-
erase activity was quantitated in a luminometer using the Dual-Lucif-
erase-Reporter system (Promega, USA). pc-fos promoter reporter was
transfected following the same procedure.
2.6. EGFP-CHIF-1K kinase assay
COS-7 cells grown in 25 cm2 £asks were transfected with the
pEGFP-CHIF-1K or EGFP expression vectors using DOTAP trans-
fection reagent (Boehringer, Germany). HMEC-1 were also grown in
25 cm2 £asks and incubated in normoxia or in hypoxia in the presence
of 20 WM PD98059. COS-7 cells were lysed with the lysis bu¡er (Tris
40 mM pH 7.5, KCl 300 mM, EDTA 2 mM, Triton X-100 1%)
containing protease inhibitors but not phosphatase inhibitors.
HMEC-1 were also lysed with the same bu¡er but containing phos-
phatase inhibitors. ERK1, EGFP and EGFP-CHIF-1K were immu-
noprecipitated using the procedure described above with respectively
ERK1 (1/1000) (Santa Cruz Biotechnology) and EGFP antibodies (1/
1000) (Clontech, USA). Then EGFP-CHIF-1K and EGFP were incu-
bated together with ERK1 samples during 1 h in kinase assay bu¡er
(described above), with 2 Wl of ATP 1 mM, 1 Wl of [Q-32P]dATP (10
WCi) and under agitation. At last, the samples were loaded on a 12%
polyacrylamide gel. The gel was dried and phospho-proteins were
revealed by autoradiography and quantitated by phospho-imager
(Packard, USA).
3. Results
3.1. ERK1 and ERK2 MAPKs are phosphorylated during
hypoxia
Phosphorylation of the HIF-1K sub-unit seems to be im-
portant for HIF-1K stabilization and hence HIF-1 activation
upon hypoxia [10,13]. The identity of the kinase(s) involved in
HIF-1K phosphorylation in hypoxia is not known. Since HIF-
1K is stabilized by FGF-2 and EGF [19] hormones known to
activate MAPKs [20], we sought whether ERK1 and ERK2
MAPKs are activated during hypoxia. Active ERKs are
known to be phosphorylated among others on tyrosine
(204), this phosphorylation can be quantitated by Western
blot analysis. HMEC-1 were incubated during increasing
time (0.5, 1 and 2 h) in either hypoxia (1% O2) or normoxia
(21% O2). Then the cells were lysed for total protein extract
Fig. 1. A: Western blot analysis of ERK1 and ERK2 phosphory-
lation. HMEC-1 were incubated during 0.5, 1 and 2 h in either nor-
moxia or hypoxia. Total proteins were extracted and blotted on
PVDF membrane. Phospho-ERKs were probed with an anti-phos-
pho p42/p44 antibody. B: A Western blot was performed on the
same extracts using monoclonal anti-ERK1 and anti-ERK2 in order
to quantitate the total amount of ERKs loaded. C: Western blot
analysis of HIF-1K protein amount during hypoxia and normoxia.
D: K-Tubulin control for the amount of proteins loaded on the gel.
E: Comparison of ERK phosphorylation in either hypoxic condi-
tions (0.5 h, 1% O2) or with EGF stimulation (0.5 h, 10 ng/ml).
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preparation. 5 Wg of total protein extracts were loaded on
polyacrylamide gel for Western blot analysis. Using an anti-
phospho-ERK antibody which recognizes the active forms of
ERK1 and ERK2 [16], an increase in both ERK1 and ERK2
phosphorylation was observed during hypoxia (Fig. 1A). Us-
ing monoclonal antibodies raised against total ERK1 and
ERK2, no modi¢cation in the level of ERK kinases expres-
sion was detected (Fig. 1B). This indicates that the increase in
ERKs phosphorylation was not due to an increase in total
ERK proteins. Hypoxia also leads to the rapid stabilization
of HIF-1K detected by Western blot analysis, with similar
kinetics (Fig. 1C). K-Tubulin was used as control for the total
amount of proteins loaded on the gel (Fig. 1D). We also
compared the ERKs phosphorylation level following hypoxia
or EGF stimulation of a known ERK activator. Both EGF
and hypoxia induced ERKs phosphorylation to similar levels
(Fig. 1E).
3.2. ERK1 and ERK2 are translocated into the nucleus during
hypoxia
Phosphorylation of cytosolic ERKs by the cytosolic MAPK
kinase MEK1 leads to their activation [21,22]. They are then
translocated within the nucleus where they will phosphorylate
various substrates such as transcription factors (c-jun, c-myc,
Elk-1) [21,22]. Since hypoxia induces the phosphorylation
of ERKs, we looked for their translocation into the nu-
cleus. Immuno£uorescence experiments were performed on
HMEC-1 incubated during 2 h in either normoxia or hypoxia.
Monoclonal anti-ERK1 and anti-ERK2 were used as primary
antibodies and anti-mouse TRITC-conjugated antibodies were
used as secondary antibodies. In normoxia, ERK1 is perinu-
clear while ERK2 is located throughout the cytosol (Fig. 2). A
clear translocation of both ERK1 and ERK2 was observed
after 2 h of hypoxia (Fig. 2).
3.3. ERK1 and ERK2 activity increase during hypoxia
In order to con¢rm ERK activation during hypoxia, we
performed a kinase assay using a EGF-R peptide which is a
substrate for ERK kinases. HMEC-1 were incubated during
2 h in either normoxia or hypoxia and with or without PD98059
(20 WM), an inhibitor of the ERK kinase pathway [14]. Then
the cells were lysed and ERK1 or ERK2 were immunopreci-
pitated using a rabbit anti-ERK2 antibody or a goat anti-
ERK1 antibody. None of these antibodies cross-reacts with
the other ERK. Immunoprecipitated proteins were then incu-
bated 30 min with [Q-32P]ATP and the peptide substrate. In-
corporated radiolabelled ATP was quantitated in a scintilla-
tion counter. As shown in Fig. 3A activation of ERK1 and of
ERK2 was observed in hypoxia compared to normoxia. This
activation was completely inhibited when cells were incubated
in the presence of PD98059 (20 WM). The total amount of
immunoprecipitated ERK1 and ERK2 was analyzed by West-
ern blotting. As shown in Fig. 3B the same amount of ERK
kinase was immunoprecipitated for each condition.
3.4. ERK kinases are not involved in HIF-1K stabilization
during hypoxia
Results shown here indicate that hypoxia induces phos-
phorylation, nuclear translocation and activation of ERK1
and ERK2. We next investigated whether these kinases are
involved in the hypoxia-induced stabilization of HIF-1K and
activation of HIF-1. The e¡ect of PD98059 on HIF-1K stabi-
lization upon hypoxia was ¢rst studied. Western blot analysis
using anti-HIF-1K antibody was performed on protein ex-
Fig. 2. Immuno£uorescence detection of ERK1 and ERK2 in both normoxia and hypoxia. HMEC-1 were incubated during 2 h in either nor-
moxia or hypoxia. Then the cells were labelled with ERK1 or ERK2 antibodies and TRITC-conjugated secondary antibody. Sub-cellular local-
ization of ERK1 and ERK2 was observed with a confocal microscope (magni¢cation 400U).
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tracts from normoxic and hypoxic HMEC-1 incubated with
or without 20 WM PD98059. In normoxia, HIF-1K is rapidly
degraded and no protein is detectable (Fig. 3C). In hypoxia
the protein is stabilized and is detected by Western blotting
(Fig. 3C). PD98059 did not inhibit the hypoxia-induced stabi-
lization of HIF-1K (Fig. 3C). This result is in accordance with
the results from Semenza [23] and Salceda [13] who showed
that PD98059 did not inhibit the hypoxia-induced DNA bind-
ing activity of HIF-1 upon hypoxia. Moreover, using the
HIF-1K antibody to a dilution 1/1000 and extensive exposi-
tion time, we were able to detect HIF-1K phosphorylation
(Fig. 3C). This phosphorylation is present in hypoxia and is
inhibited in the presence of PD98059 (Fig. 3C). A control of
phosphorylation was performed using extracts which were not
treated with phosphatase inhibitors (Fig. 3C). All together,
these results indicate that ERKs are not involved in HIF-1K
stabilization nor in the regulation of the DNA binding activity
of HIF-1. However, HIF-1K phosphorylation is dependent on
the ERK pathway.
3.5. PD98059 inhibits the activity of HIF-1
We then investigated the role of ERK kinases in the HIF-1
transcriptional activity. HMEC-1 were transfected with a lu-
ciferase reporter gene [17] (pGL3-SV40HRE) which expres-
sion is under the control of three copies of the HRE cis-ele-
ments. The pRL-SV40 vector was used as transfection
e⁄ciency control. Transfected cells were incubated in either
normoxia or hypoxia without or in the presence of 20 WM
PD98059. 24 h later the luciferase activity was quantitated.
As shown in Fig. 4, hypoxia increased by 3.5-fold the lucifer-
ase activity indicating that HIF-1 was indeed activated in
these conditions. PD98059 strongly inhibited the HIF-1 in-
duced response to hypoxia. This result indicates that ERK
kinases could be involved in the regulation of hypoxia-in-
duced activity of HIF-1.
3.6. ERK1 but not ERK2 is involved in HIF-1 activity
In order to con¢rm that ERK kinases are indeed involved
in the regulation of HIF-1 activity, we used ERK1 and ERK2
dominant negative mutants [18]. HMEC-1 were co-transfected
with the pGL3-SV40HRE, the pRL-SV40 and either with a
null-vector or with a ERK1 or a ERK2 dominant negative
expressing vector. Thereafter, the cells were placed in normox-
ia or in hypoxia and 20 h later, the luciferase activity was
quantitated. A complete inhibition of HIF-1 activity was ob-
tained in cells transfected with the ERK1 dominant negative
(Fig. 5A). No such e¡ect was observed in cells expressing a
ERK2 dominant negative protein (Fig. 5A). This result con-
¢rms that MAPKs are actually involved in the regulation of
HIF-1 transcriptional activity upon hypoxia and that HIF-1
activation requires active ERK1. ERK1 and ERK2 kinase
dead alleles are also able to inhibit the c-fos promoter reporter
activity (Fig. 5B), this activation is induced by Elk-1 [24]
which has been identi¢ed as a ERKs target in hypoxia
[24,25]. This demonstrates that the dominant negative mu-
tants are expressed in HMEC-1 and that they are active.
This also con¢rmed ERKs activation upon hypoxia.
3.7. The HIF-1K carboxy-terminal domain is phosphorylated
by ERK1
Inhibition of HIF-1 activity by ERK1 dominant negative
does not indicate that ERK1, while activated by hypoxia is
able to directly phosphorylate the HIF-1 sub-units. Salceda
and Semenza proposed that the carboxy-terminal domain of
HIF-1K is also regulated independently of the HIF-1 DNA
binding activity [11,13] and that this regulation involves phos-
phorylation(s). That is why we tested the capability of hypoxi-
cally activated ERK1 to directly phosphorylate the carboxy-
terminal domain of HIF-1K. COS-7 cells were transfected
with the pEGFP-CHIF-1K (carboxy terminal domain of
Fig. 3. Quanti¢cation of ERK1 and ERK2 activity using a kinase
assay experiment. HMEC-1 were incubated 2 h in normoxia or in
hypoxia in the presence or in the absence of 20 WM of PD98059.
ERK1 and ERK2 immunoprecipitated from the cell extracts were
incubated with a peptide-substrate and [Q-32P]dATP. A: Quanti¢ca-
tion of radiolabelled phosphate incorporated in the peptide substrate
by ERK1 and ERK2. B: Western blot analysis of the amount of
ERK1 and of ERK2 immunoprecipitated for each experimental con-
dition. C: PD98059 does not inhibit HIF-1K stabilization during
hypoxia. HMEC-1 were incubated during 2 h in either normoxia or
in hypoxia in the presence or in the absence of 20 WM PD98059.
HIF-1K was detected by Western blot analysis. HIF-1K is phos-
phorylated in hypoxia and PD98059 inhibits the HIF-1K phos-
phorylation. Extracts that were not treated with phosphatase inhibi-
tors were used as phosphorylation negative control. K-Tubulin was
used as control for total protein amount loaded on the gel.
Fig. 4. PD98059 inhibits the hypoxia-induced transcriptional activity
of HIF-1. HMEC-1 were transfected with the pGL3-SV40HRE to-
gether with the pRL-SV40 control vector. Then the cells were incu-
bated 24 h in either normoxia or hypoxia in the absence or in the
presence of 20 WM PD98059. Thereafter, the cells were lysed for lu-
ciferase assays. Data represent the ratio between test ¢re£y lucifer-
ase activity and renilla luciferase activity (RF/R). Results are pre-
sented as means þ S.D. for triplicates.
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HIF-1K) vector which expresses a EGFP-CHIF-1K chimeric
protein or with the pEGFP as a negative control. Then the
cells were lysed and EGFP-CHIF-1K or EGFP proteins were
immunoprecipitated using anti-EGFP antibodies. In parallel,
ERK1 proteins were immunoprecipitated from HMEC-1 in-
cubated 2 h in normoxia or in hypoxia in the presence or in
the absence of 20 WM PD98059. Then EGFP-CHIF-1K was
incubated with [Q-P32]dATP in the presence of the di¡erent
ERK1 samples. EGFP was incubated in the presence of
ERK1 immunoprecipitated from hypoxic HMEC-1. The sam-
ples were then loaded on a polyacrylamide gel. As shown in
Fig. 6A,B, the HIF-1K carboxy-terminal domain is phosphor-
ylated by ERK1, activated by hypoxia and PD98059 indeed
inhibited the HIF-1K phosphorylation. EGFP is not
phosphorylated by ERK1. The amount of immunoprecipi-
tated ERK1 is similar in all samples as shown by Western
blot (Fig. 6C). These results indicate that the carboxy-termi-
nal domain of HIF-1K can be directly phosphorylated by
ERK1 kinase only when activated by hypoxia.
4. Discussion
Phosphorylation plays a key role in transcription factor
regulation. HIF-1 is a transcription factor speci¢cally acti-
vated under hypoxic conditions [1]. Its phosphorylation is
necessary to obtain its activation [10,13]. Semenza et al. dem-
onstrated that the carboxy-terminal domain of HIF-1K is in-
volved in the transactivation of hypoxia-responsive reporter
genes [11]. Hence, it appears that HIF-1 regulation involves at
least two mechanisms: regulation of the HIF-1K degradation
and regulations occurring at the transactivation domain.
Phosphorylation seems to be an important way of regulating
HIF-1 activity. These data infers a transduction pathway from
a putative oxygen sensor to unidenti¢ed kinase(s).
HIF-1K stabilization was observed in the presence of EGF
[19]. EGF is known to activate the ERKs MAPK pathway
[19,20]. Interestingly, Mukhopadhyay et al. demonstrated that
6-thioguanine an ERK inhibitor, impairs the hypoxic activa-
tion of the expression of the VEGF gene [26]. Salceda et al.
also showed that PD98059, an inhibitor of the ERKs up-
stream kinase MEK1, was able to impair the HIF-1 induced
transactivation activity but did not inhibit its DNA binding
activity [13]. In order to search for kinases activated in hy-
poxic conditions, we investigated the putative role of
MAPK(s) in HIF-1 activation. In this report, we indeed
showed that in HMEC-1, hypoxia is able to induce the phos-
phorylation of both ERK1 and ERK2 MAPKs. This phos-
phorylation led to their nuclear translocation and to their
activation as assessed by a kinase assay and c-fos promoter
reporter assay.
We then sought whether the activation of ERK kinases by
hypoxia is involved in the HIF-1-dependent response. As
HIF-1K is a cytosolic protein rapidly degraded by the protea-
some [5,6] and ERK are nuclear active kinases [21,22], we
presumed that MAPKs were not involved in the hypoxic sta-
bilization mechanism of HIF-1K. Indeed, treatment with an
ERK inhibitor (PD98059) did not impair the HIF-1K stabili-
zation in hypoxia nor did it impair the DNA binding activity
of HIF-1 as shown by Salceda and Semenza [13,23], but it is
involved in HIF-1K phosphorylation.
On the other hand, in HMEC-1, PD98059 was able to in-
hibit the hypoxia-induced transcription of a reporter gene
which is regulated by HRE cis-elements. Inhibition observed
with dominant negative mutants of ERK1 and ERK2 con-
¢rmed in vivo that ERKs MAPKs are activated by hypoxia
as assayed with the c-fos promoter reporter and that ERK1 is
involved in the activation of HIF-1 transcriptional activity by
hypoxia whereas ERK2 did not seem to be involved. More-
over, we showed that ERK1 activated by hypoxia is able to
directly phosphorylate the HIF-1K carboxy-terminal domain.
Interestingly, the HIF-1K ID domain contains several X-X-S-
P [27] motives which are putative phosphorylation sites for
ERKs. However, the regulation of HIF-1 activity by ERK1
Fig. 6. Phosphorylation of the carboxy-terminal domain of HIF-1K
by ERK1. Immunoprecipitated EGFP-CHIF-1K was incubated with
immunoprecipitated ERK1 from HMEC-1 incubated in either nor-
moxia (N) or hypoxia (H) in the presence (+) or in the absence (3)
of 20 WM PD98059 (A). EGFP was used as negative control and in-
cubated with ERK1 from hypoxic HMEC-1 (A). The amount of
phospho-EGFP-CHIF-1K was quantitated in a phospho-imager (B).
The amount of immunoprecipitated ERK1 was quantitated by
Western blot (C).
Fig. 5. ERK1 but not ERK2 dominant negative mutants inhibit
HIF-1 transcriptional activity. HMEC-1 were cotransfected with the
pGL3-SV40HRE (A) or pc-fos (B) together with the pRL-SV40
control vector and with either a null vector (pBSKII) or a dominant
negative ERK1 vector (pcDNA-ERK1-) or a dominant negative
ERK2 vector (pcDNA-ERK2-). The cells were incubated 20 h in ei-
ther normoxia or hypoxia. The cells were lysed for luciferase assays.
Data represent the ratio between test ¢re£y luciferase activity and
renilla luciferase activity (RF/R). Results are presented as
means þ S.D. for triplicates.
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could also involve phosphorylation of co-activator(s) [12].
This has to be tested.
The nature of the transduction pathway from the putative
oxygen sensor to the activation of kinases is still unknown.
Several models were hypothesized [1,28]. Interestingly in cells
unable of mitochondrial respiration following mitochondrial
DNA deletion, HIF-1 activation is inhibited in hypoxia [28].
When hypoxic cells are treated with the reducing agents
PDTC, PDI or ebselen, HIF-1 remains inactive [1,28]. These
results suggested that mitochondrial ROS production during
hypoxia could be one event involved in the hypoxia signalling
pathway [28]. However, the increase of ROS production dur-
ing hypoxia is still much debated. Interestingly, there are
growing evidences that ERKs MAPK pathway is activated
by reactive oxygen species [29,30].
Richard et al. [31], also recently demonstrated in vitro that
ERKs are indeed able to phosphorylate HIF-1K. However
they did not detect ERKs activation upon hypoxia in their
cell line. We show here that in microvascular endothelial cells
hypoxia is able to activate ERKs MAPKs and that in vivo
ERK1 directly participates in HIF-1 activation and is able to
phosphorylate its transactivation domain. This evidences that
MAPK are involved in the transcriptional response to hypox-
ia.
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